Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
- Author:
Desmond Y. H. YAP
1
;
Kevin S. H. LIU
;
Yu-Chun HSU
;
Grace L. H. WONG
;
Ming-Chang TSAI
;
Chien-Hung CHEN
;
Ching-Sheng HSU
;
Yee Tak HUI
;
Michael K. K. LI
;
Chen-Hua LIU
;
Yee-Man KAN
;
Ming-Lung YU
;
Man-Fung YUEN
Author Information
- Publication Type:Original Article
- From:Clinical and Molecular Hepatology 2020;26(4):554-561
- CountryRepublic of Korea
- Language:0
-
Abstract:
Background/Aims:Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to study the treatment and side effects of GLE/PIB in these patients infected with non-1 genotype (GT) HCV.
Methods:We prospectively recruited patients with Child’s A cirrhosis and eGFR <30 mL/min/1.73 m2 in Hong Kong and Taiwan during 2017–2018 to receive GLE/PIB treatment.
Results:Twenty-one patients (GT2, n=7; GT3, n=6; and GT6, n=8) received GLE/PIB for 11.2±1.8 weeks. All except one were treatment-naïve. GLE/PIB was initiated in 16 patients while on dialysis (seven on peritoneal dialysis [PD] and nine on hemodialysis) and in five patients before dialysis. One patient died of PD-related peritonitis during treatment and two were lost to follow up. The SVR12 rate in the remaining 18 patients was 100%. All patients achieved undetectable levels at 4-, 12-, 24- and 48-week after treatment. Patients with deranged alanine aminotransferase showed normalization after 4 weeks and the response was sustained for 48 weeks. No significant adverse event was observed.
Conclusions:GLE/PIB treatment was associated with high efficacy and tolerability in HCV-infected patients with severe renal impairment.
